Angèle Consoli

Bio: Angèle Consoli is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Catatonia & Population. The author has an hindex of 25, co-authored 68 publications receiving 1744 citations. Previous affiliations of Angèle Consoli include University of Picardie Jules Verne & Paris Descartes University.

Tentatives de suicide chez les adolescents français de 17 ans : données de l’étude ESCAPAD 2008

Abstract: Resume Interet Le suicide des enfants et des adolescents constitue un probleme majeur de sante publique. Les antecedents de tentative de suicide (TS) sont un facteur de risque bien etabli de suicide. L’hospitalisation des enfants et des adolescents suite a une TS est recommandee par les agences sanitaires francaises depuis 1998. Objectifs Cette etude a pour objectifs d’estimer la frequence des TS au cours de l’enfance et l’adolescence et le pourcentage d’hospitalisation suite a une TS. Methode Cette etude se base sur l’enquete ESCAPAD, qui a ete menee pendant la Journee d’appel de preparation a la defense de 2008. Des analyses statistiques bivariees ont compare les caracteristiques sociodemographiques et les perceptions des relations intrafamiliales des adolescents ayant au moins un antecedent de TS et de ceux sans antecedent de TS. Resultats Parmi les adolescents qui ont participe a l’etude ESCAPAD en 2008, 8,2 % (n = 3146) rapportent au moins un antecedent de TS. Par rapport aux adolescents qui n’ont aucun antecedent de TS, ceux qui ont au moins un antecedent de TS sont plus frequemment de sexe feminin (sex-ratio 1:3) et descolarises au moment de l’enquete ; ils ont plus souvent redouble une classe ainsi que des parents sans emploi. De maniere notable, les adolescents qui ont au moins un antecedent de TS rapportent plus frequemment de mauvaises relations avec leur pere, leur mere et/ou de mauvaises relations entre les parents. Seulement 25 % des adolescents ayant des antecedents de TS ont ete hospitalises suite a cette TS. Discussion Cette etude souligne la frequence elevee des TS au cours de l’enfance et de l’adolescence ainsi que le faible taux d’hospitalisation suite a ces TS.

Bipolar Disorder Type 1 in a 17-Year-Old Girl with Wolfram Syndrome.

Abstract: Objective: Wolfram syndrome (WS, MIM 222300) is a rare autosomal, recessive neurodegenerative disorder associated with mutations in WFS1, a gene that has been associated with bipolar disorder (BD). WS, characterized by the association of juvenile-onset diabetes mellitus (DM) and bilateral progressive optic atrophy (BPOA), encompasses several other clinical features, including cognitive impairments and psychiatric disorders. Detailed data on the psychiatric phenotype are still scarce, and how WS relates to BD is still unknown. Method: A 17-year-old girl with WS was hospitalized for early-onset BD. A multidisciplinary and developmental assessment was carried out to control mood symptoms and address how BD could be related to WS. Results: Besides DM and BPOA, the patient had several risk factors for BD/mood disorders as follows: (1) a history of abuse and maltreatment; (2) a history of specific language disorder and borderline intelligence associated with academic failure; and (3) a comorbid hypothy...

Traitement par lithium dans le trouble bipolaire du sujet jeune

Abstract: Resume La pharmacologie dans les troubles bipolaires chez l’enfant et l’adolescent beneficie d’un interet croissant mais peu d’etudes concernent le lithium. L’efficacite du lithium en monotherapie est moderee, avec des taux de reponse de l’ordre de 35 a 63 %. Le benefice des combinaisons therapeutiques (association au divalproate de sodium, a la carbamazepine ou a la risperidone) est net avec des taux de reponse atteignant 70 a 90 %. Le taux de rechute sous lithium en monotherapie est eleve (37 a 56 %) mais peu etudie. Si le profil de tolerance du lithium est rassurant, les effets secondaires rapportes semblent plus frequents que chez l’adulte, et l’on ne dispose d’aucune donnee a long terme. Enfin, la lisibilite de tous ces resultats souffre d’une limite majeure liee a l’heterogeneite clinique avec l’usage extensif du diagnostic de bipolarite chez l’enfant prepubere. Les etudes futures beneficieront du cadre diagnostique distinguant les diagnostics de « Dysregulation Emotionnelle Severe » (ou « Temper Dysregulation Disorder with Dysphoria » dans le DSM-5) chez l’enfant et de trouble bipolaire de type I chez l’adolescent.

Relevance of Brain 18F-FDG PET Imaging in Probable Seronegative Encephalitis With Catatonia: A Case Report.

Abstract: Autoimmune encephalitis (AIE) is a rare, severe, and rapidly progressive encephalopathy, and its diagnosis is challenging, especially in adolescent populations when the presentation is mainly psychiatric. Currently, cerebral 18-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) imaging is not included in the diagnosis algorithm. We describe a 16-year-old patient with probable seronegative encephalitis with catatonia for which several cerebral PET scans were relevant and helpful for diagnosis, treatment decision making, and follow-up monitoring. The patient recovered after 2 years of treatment with etiologic treatment of AIE and treatment of catatonia. This case suggests a more systematic assessment of the clinical relevance of 18F-FDG-PET imaging in probable seronegative AIE.

Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

Abstract: Schizophrenia (SCZ) is a chronic mental illness and among the most debilitating conditions encountered in medical practice. A recent landmark SCZ study of the protein-coding regions of the genome identified a causal role for ten genes and a concentration of rare variant signals in evolutionarily constrained genes1. This recent study-and most other large-scale human genetics studies-was mainly composed of individuals of European (EUR) ancestry, and the generalizability of the findings in non-EUR populations remains unclear. To address this gap, we designed a custom sequencing panel of 161 genes selected based on the current knowledge of SCZ genetics and sequenced a new cohort of 11,580 SCZ cases and 10,555 controls of diverse ancestries. Replicating earlier work, we found that cases carried a significantly higher burden of rare protein-truncating variants (PTVs) among evolutionarily constrained genes (odds ratio = 1.48; P = 5.4 × 10-6). In meta-analyses with existing datasets totaling up to 35,828 cases and 107,877 controls, this excess burden was largely consistent across five ancestral populations. Two genes (SRRM2 and AKAP11) were newly implicated as SCZ risk genes, and one gene (PCLO) was identified as shared by individuals with SCZ and those with autism. Overall, our results lend robust support to the rare allelic spectrum of the genetic architecture of SCZ being conserved across diverse human populations.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Abstract: The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009. This third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunction with the previous publications.The recommendations for the management of acute mania remain largely unchanged. Lithium, valproate, and several atypical antipsychotic agents continue to be first-line treatments for acute mania. Monotherapy with asenapine, paliperidone extended release (ER), and divalproex ER, as well as adjunctive asenapine, have been added as first-line options.For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, as well as olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. Lurasidone monotherapy and the combination of lurasidone or lamotrigine plus lithium or divalproex have been added as a second-line options. Ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have been added as not-recommended options for the treatment of bipolar depression. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone long-acting injection, and adjunctive ziprasidone continue to be first-line options for maintenance treatment of bipolar disorder. Asenapine alone or as adjunctive therapy have been added as third-line options.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

Abstract: The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the International Society for Bipolar Disorders (ISBD), reviews new evidence and is designed to be used in conjunction with the previous publications. The recommendations for the management of acute mania remain mostly unchanged. Lithium, valproate, and several atypical antipsychotics continue to be first-line treatments for acute mania. Tamoxifen is now suggested as a third-line augmentation option. The combination of olanzapine and carbamazepine is not recommended. For the management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalproex plus SSRI/bupropion remain first-line options. New data support the use of adjunctive modafinil as a second-line option, but also indicate that aripiprazole should not be used as monotherapy for bipolar depression. Lithium, lamotrigine, valproate, and olanzapine continue to be first-line options for maintenance treatment of bipolar disorder. New data support the use of quetiapine monotherapy and adjunctive therapy for the prevention of manic and depressive events, aripiprazole monotherapy for the prevention of manic events, and risperidone long-acting injection monotherapy and adjunctive therapy, and adjunctive ziprasidone for the prevention of mood events. Bipolar II disorder is frequently overlooked in treatment guidelines, but has an important clinical impact on patients' lives. This update provides an expanded look at bipolar II disorder.